ALNA:NSD-Allena Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.02

Change

0.00 (-13.18)%

Market Cap

USD 9.16M

Volume

0.67M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ALNA Stock Forecast & Price:
Based on the Allena Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Allena Pharmaceuticals Inc is not available over the next 12 months. Allena Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allena Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Allena Pharmaceuticals Inc’s stock price was USD 0.02. Allena Pharmaceuticals Inc’s stock price has changed by -26.54% over the past week, -81.58% over the past month and -97.93% over the last year.

About Allena Pharmaceuticals Inc (ALNA:NSD)

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degra ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+8.91 (+1.30%)

USD74.83B 13.56 10.63
VRTX Vertex Pharmaceuticals Inc

+7.96 (+2.88%)

USD72.69B 23.18 15.56
MRNA Moderna Inc

+2.54 (+2.12%)

USD48.37B 3.83 2.59
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.65 (+2.08%)

USD31.55B 2.99 1.31
RPRX Royalty Pharma Plc

+0.35 (+0.88%)

USD27.26B 39.16 19.50
SGEN Seagen Inc

+0.08 (+0.06%)

USD24.95B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

+5.22 (+2.64%)

USD23.69B N/A -31.40
GMAB Genmab AS

+0.30 (+0.95%)

USD21.80B 40.29 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALNA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -96.78% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.78% 1% F 1% F
Trailing 12 Months  
Capital Gain -97.87% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.87% 1% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -50.97% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.97% 1% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.17% 78% C+ 54% F
Risk Adjusted Return -163.54% 1% F N/A N/A
Market Capitalization 9.16M 7% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.86 50% F 41% F
Price / Cash Flow Ratio -0.20 11% F 42% F
EV/EBITDA -0.13 38% F 51% F
Management Effectiveness  
Return on Equity -541.02% 5% F 4% F
Return on Invested Capital -155.86% 12% F 11% F
Return on Assets -106.64% 4% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.62 83% B 76% C
Short Percent 8.54% 24% F 18% F
Beta 1.15 51% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.